139 related articles for article (PubMed ID: 29416779)
1. The sphingosine kinase 2 inhibitor ABC294640 inhibits cervical carcinoma cell growth.
Xu L; Jin L; Yang B; Wang L; Xia Z; Zhang Q; Xu J
Oncotarget; 2018 Jan; 9(2):2384-2394. PubMed ID: 29416779
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of ceramide glucosylation sensitizes lung cancer cells to ABC294640, a first-in-class small molecule SphK2 inhibitor.
Guan S; Liu YY; Yan T; Zhou J
Biochem Biophys Res Commun; 2016 Aug; 476(4):230-236. PubMed ID: 27221045
[TBL] [Abstract][Full Text] [Related]
3. Targeting sphingosine kinase 2 by ABC294640 inhibits human skin squamous cell carcinoma cell growth.
Zhou J; Chen J; Yu H
Biochem Biophys Res Commun; 2018 Mar; 497(2):535-542. PubMed ID: 29428730
[TBL] [Abstract][Full Text] [Related]
4. Targeting sphingosine kinase 2 (SphK2) by ABC294640 inhibits colorectal cancer cell growth in vitro and in vivo.
Xun C; Chen MB; Qi L; Tie-Ning Z; Peng X; Ning L; Zhi-Xiao C; Li-Wei W
J Exp Clin Cancer Res; 2015 Sep; 34(1):94. PubMed ID: 26337959
[TBL] [Abstract][Full Text] [Related]
5. Targeting sphingosine kinase 2 suppresses cell growth and synergizes with BCL2/BCL-XL inhibitors through NOXA-mediated MCL1 degradation in cholangiocarcinoma.
Ding X; Zhang Y; Huang T; Xu G; Peng C; Chen G; Kong B; Friess H; Shen S; Lv Y; Roberts LR; Wang L; Zou X
Am J Cancer Res; 2019; 9(3):546-561. PubMed ID: 30949409
[TBL] [Abstract][Full Text] [Related]
6. Targeting SphK2 Reverses Acquired Resistance of Regorafenib in Hepatocellular Carcinoma.
Shi W; Zhang S; Ma D; Yan D; Zhang G; Cao Y; Wang Z; Wu J; Jiang C
Front Oncol; 2020; 10():694. PubMed ID: 32670862
[No Abstract] [Full Text] [Related]
7. Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells.
Ding X; Chaiteerakij R; Moser CD; Shaleh H; Boakye J; Chen G; Ndzengue A; Li Y; Zhou Y; Huang S; Sinicrope FA; Zou X; Thomas MB; Smith CD; Roberts LR
Oncotarget; 2016 Apr; 7(15):20080-92. PubMed ID: 26956050
[TBL] [Abstract][Full Text] [Related]
8. Sphingosine kinase 2 inhibitor ABC294640 displays anti-epithelial ovarian cancer activities in vitro and in vivo.
Song K; Dai L; Long X; Cui X; Liu Y; Di W
Onco Targets Ther; 2019; 12():4437-4449. PubMed ID: 31239712
[No Abstract] [Full Text] [Related]
9. Targeting ovarian cancer and chemoresistance through selective inhibition of sphingosine kinase-2 with ABC294640.
White MD; Chan L; Antoon JW; Beckman BS
Anticancer Res; 2013 Sep; 33(9):3573-9. PubMed ID: 24023282
[TBL] [Abstract][Full Text] [Related]
10. The combination of a sphingosine kinase 2 inhibitor (ABC294640) and a Bcl-2 inhibitor (ABT-199) displays synergistic anti-myeloma effects in myeloma cells without a t(11;14) translocation.
Sundaramoorthy P; Gasparetto C; Kang Y
Cancer Med; 2018 Jul; 7(7):3257-3268. PubMed ID: 29761903
[TBL] [Abstract][Full Text] [Related]
11. The Sphingosine Kinase 2 Inhibitor ABC294640 Reduces the Growth of Prostate Cancer Cells and Results in Accumulation of Dihydroceramides In Vitro and In Vivo.
Venant H; Rahmaniyan M; Jones EE; Lu P; Lilly MB; Garrett-Mayer E; Drake RR; Kraveka JM; Smith CD; Voelkel-Johnson C
Mol Cancer Ther; 2015 Dec; 14(12):2744-52. PubMed ID: 26494858
[TBL] [Abstract][Full Text] [Related]
12. SphK2/S1P Promotes Metastasis of Triple-Negative Breast Cancer Through the PAK1/LIMK1/Cofilin1 Signaling Pathway.
Shi W; Ma D; Cao Y; Hu L; Liu S; Yan D; Zhang S; Zhang G; Wang Z; Wu J; Jiang C
Front Mol Biosci; 2021; 8():598218. PubMed ID: 33968977
[TBL] [Abstract][Full Text] [Related]
13. A novel sphingosine kinase inhibitor induces autophagy in tumor cells.
Beljanski V; Knaak C; Smith CD
J Pharmacol Exp Ther; 2010 May; 333(2):454-64. PubMed ID: 20179157
[TBL] [Abstract][Full Text] [Related]
14. Sphingosine kinase inhibition exerts both pro- and anti-atherogenic effects in low-density lipoprotein receptor-deficient (LDL-R(-/-)) mice.
Poti F; Bot M; Costa S; Bergonzini V; Maines L; Varga G; Freise H; Robenek H; Simoni M; Nofer JR
Thromb Haemost; 2012 Mar; 107(3):552-61. PubMed ID: 22234485
[TBL] [Abstract][Full Text] [Related]
15. Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2.
French KJ; Zhuang Y; Maines LW; Gao P; Wang W; Beljanski V; Upson JJ; Green CL; Keller SN; Smith CD
J Pharmacol Exp Ther; 2010 Apr; 333(1):129-39. PubMed ID: 20061445
[TBL] [Abstract][Full Text] [Related]
16. ABC294640, A Novel Sphingosine Kinase 2 Inhibitor, Induces Oncogenic Virus-Infected Cell Autophagic Death and Represses Tumor Growth.
Dai L; Bai A; Smith CD; Rodriguez PC; Yu F; Qin Z
Mol Cancer Ther; 2017 Dec; 16(12):2724-2734. PubMed ID: 28939554
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of Critical Oncogenes by the Selective SK2 Inhibitor ABC294640 Hinders Prostate Cancer Progression.
Schrecengost RS; Keller SN; Schiewer MJ; Knudsen KE; Smith CD
Mol Cancer Res; 2015 Dec; 13(12):1591-601. PubMed ID: 26271487
[TBL] [Abstract][Full Text] [Related]
18. Proteasomal degradation of sphingosine kinase 1 and inhibition of dihydroceramide desaturase by the sphingosine kinase inhibitors, SKi or ABC294640, induces growth arrest in androgen-independent LNCaP-AI prostate cancer cells.
McNaughton M; Pitman M; Pitson SM; Pyne NJ; Pyne S
Oncotarget; 2016 Mar; 7(13):16663-75. PubMed ID: 26934645
[TBL] [Abstract][Full Text] [Related]
19. Ceramides promote apoptosis for virus-infected lymphoma cells through induction of ceramide synthases and viral lytic gene expression.
Dai L; Trillo-Tinoco J; Bai A; Chen Y; Bielawski J; Del Valle L; Smith CD; Ochoa AC; Qin Z; Parsons C
Oncotarget; 2015 Sep; 6(27):24246-60. PubMed ID: 26327294
[TBL] [Abstract][Full Text] [Related]
20. Blockage of PTPRJ promotes cell growth and resistance to 5-FU through activation of JAK1/STAT3 in the cervical carcinoma cell line C33A.
Yan CM; Zhao YL; Cai HY; Miao GY; Ma W
Oncol Rep; 2015 Apr; 33(4):1737-44. PubMed ID: 25634668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]